{"protocolSection":{"identificationModule":{"nctId":"NCT00409006","orgStudyIdInfo":{"id":"10918"},"secondaryIdInfos":[{"id":"H3E-AA-S110","type":"OTHER","domain":"Eli Lilly and Company"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers","officialTitle":"A Phase 2 Trial of Pemetrexed and Cisplatin Followed Sequentially by Gefitinib Versus Pemetrexed and Cisplatin in Asian \"Never Smoker\" Patients With Advanced Non-Small Cell Lung Cancer"},"statusModule":{"statusVerifiedDate":"2010-08","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2007-02"},"primaryCompletionDateStruct":{"date":"2009-08","type":"ACTUAL"},"completionDateStruct":{"date":"2010-05","type":"ACTUAL"},"studyFirstSubmitDate":"2006-12-06","studyFirstSubmitQcDate":"2006-12-06","studyFirstPostDateStruct":{"date":"2006-12-08","type":"ESTIMATED"},"resultsFirstSubmitDate":"2010-08-13","resultsFirstSubmitQcDate":"2010-08-13","resultsFirstPostDateStruct":{"date":"2010-09-09","type":"ESTIMATED"},"lastUpdateSubmitDate":"2010-08-13","lastUpdatePostDateStruct":{"date":"2010-09-09","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"oldNameTitle":"Chief Medical Officer","oldOrganization":"Eli Lilly"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The purpose of this study is to compare the efficacy and safety of chemotherapy followed sequentially by gefitinib versus chemotherapy alone in the first line treatment of non-small cell lung cancer (NSCLC). This study will be conducted in Asian patients who are classified as 'never smoker' since it is suggested that these patients are more likely to respond favorably to treatment with gefitinib."},"conditionsModule":{"conditions":["Non-small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":70,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Pemetrexed/Cisplatin/Gefitinib","type":"EXPERIMENTAL","description":"Pemetrexed 500 milligrams per meters squared (mg/m2) plus cisplatin 75 mg/m2 administered by intravenous (IV) infusion once every 3 weeks for 4 cycles without progression followed by gefitinib 250 mg administered orally, once daily, until disease progression or unacceptable toxicity.","interventionNames":["Drug: Pemetrexed","Drug: Cisplatin","Drug: Gefitinib"]},{"label":"Pemetrexed/Cisplatin","type":"EXPERIMENTAL","description":"Pemetrexed 500 milligrams per meters squared (mg/m2) plus cisplatin 75 mg/m2 administered by intravenous (IV) infusion once every 3 weeks for 4 cycles without progression followed by pemetrexed 500 mg/m2 administered by IV infusion (with optional cisplatin 75 mg/m2 for up to 2 additional cycles) until disease progression or unacceptable toxicity.","interventionNames":["Drug: Pemetrexed","Drug: Cisplatin"]}],"interventions":[{"type":"DRUG","name":"Pemetrexed","description":"500 milligrams per meter squared (mg/m2), administered by intravenous (IV) infusion every 21 days for 4 cycles (1-4) or 500 mg/m2, IV, every 21 days until disease progression or unacceptable toxicity.","armGroupLabels":["Pemetrexed/Cisplatin","Pemetrexed/Cisplatin/Gefitinib"],"otherNames":["LY231514","Alimta"]},{"type":"DRUG","name":"Cisplatin","description":"75 mg/m2, IV, every 21 days for 4 cycles (1-4) or 75 mg/m2, IV, every 21 days for 4 cycles with optional continuation for 2 additional cycles until disease progression or unacceptable toxicity","armGroupLabels":["Pemetrexed/Cisplatin","Pemetrexed/Cisplatin/Gefitinib"]},{"type":"DRUG","name":"Gefitinib","description":"250 mg, administered orally once daily beginning at Cycle 5 until disease progression or unacceptable toxicity","armGroupLabels":["Pemetrexed/Cisplatin/Gefitinib"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression-Free Survival (PFS)","description":"Defined as the time from randomization to the first observation of disease progression, or death due to any cause.","timeFrame":"Baseline to first observation of disease progression or death, 12 weeks up to 31 months"}],"secondaryOutcomes":[{"measure":"Number of Participants With Tumor Response","description":"Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes not meeting above criteria. Responder is a participant exhibiting a best overall study response of CR or PR.","timeFrame":"Baseline to measured response or death, 12 weeks up to 31 months"},{"measure":"Duration of Response for Responders","description":"The duration of a complete response (CR; the disappearance of all target lesions) or partial response (PR; at least a 30% decrease in the sum of the longest diameter of target lesions) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause. A responder is a patient exhibiting a best overall study response of CR or PR.","timeFrame":"Time of response to progressive disease or death, 12 weeks up to 31 months"},{"measure":"Overall Survival","description":"Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact. Median overall survival could not be estimated as most participants were living at the end of the study. 25 participants from each treatment group were censored. In place of this outcome measure, the percentage of participants who died during the study are provided in the Post-Hoc Analysis Outcome Measure: Percentage of Participants Who Died During the Study.","timeFrame":"Baseline to date of death from any cause, 12 weeks up to 31 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologic or cytologic diagnosis non-small cell lung cancer (NSCLC) (Stage IIIB or IV)\n* Have not received any prior chemotherapy, molecular therapy, immunotherapy, biological therapy, or radiotherapy. Exception: palliative radiotherapy that is completed at least 4 weeks prior to study enrolment.\n* Have 'never smoked' (defined as having smoked \\<100 cigarettes during his/her lifetime)\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1\n\nExclusion Criteria:\n\n* Concurrent administration of any other tumor therapy\n* Other co-existing malignancies\n* Pregnancy or breast feeding\n* Serious concomitant disorders\n* Inability or unwillingness to take folic acid or vitamin B12 supplementation","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Fujian","zip":"350014","country":"China","geoPoint":{"lat":28.92651,"lon":106.12972}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Qingdao","zip":"266003","country":"China","geoPoint":{"lat":36.06488,"lon":120.38042}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Shanghai","zip":"201900","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Seoul","zip":"137-701","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Changhua","zip":"500","country":"Taiwan","geoPoint":{"lat":24.0692,"lon":120.5512}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Taipei","zip":"100","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Taoyuan District","zip":"333","country":"Taiwan","geoPoint":{"lat":24.9896,"lon":121.3187}}]},"referencesModule":{"references":[{"pmid":"22534669","type":"DERIVED","citation":"Ahn MJ, Yang JC, Liang J, Kang JH, Xiu Q, Chen YM, Blair JM, Peng G, Linn C, Orlando M. Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer. Lung Cancer. 2012 Aug;77(2):346-52. doi: 10.1016/j.lungcan.2012.03.011. Epub 2012 Apr 23."}],"seeAlsoLinks":[{"label":"Lilly Clinical Trial Registry","url":"http://www.lillytrials.com"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"86 participants entered study. 13 participants were screen failures. 73 participants (40 pemetrexed/cisplatin/gefitinib and 33 pemetrexed/cisplatin) were assigned to treatment. 3 participants did not receive study drug. These 16 participants (13 screen failures and 3 that did not receive drug) were not included in the analyses.","groups":[{"id":"FG000","title":"Pemetrexed/Cisplatin/Gefitinib","description":"Pemetrexed 500 milligrams per meters squared (mg/m2) plus cisplatin 75 mg/m2 administered by intravenous (IV) infusion once every 3 weeks for 4 cycles without progression followed by gefitinib 250 mg administered orally, once daily, until disease progression or unacceptable toxicity."},{"id":"FG001","title":"Pemetrexed/Cisplatin","description":"Pemetrexed 500 milligrams per meters squared (mg/m2) plus cisplatin 75 mg/m2 administered by intravenous (IV) infusion once every 3 weeks for 4 cycles without progression followed by pemetrexed 500 mg/m2 administered by IV infusion (with optional cisplatin 75 mg/m2 for up to 2 additional cycles) until disease progression or unacceptable toxicity."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"39"},{"groupId":"FG001","numSubjects":"31"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"19"},{"groupId":"FG001","numSubjects":"19"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"20"},{"groupId":"FG001","numSubjects":"12"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"6"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Pemetrexed/Cisplatin/Gefitinib","description":"Pemetrexed 500 milligrams per meters squared (mg/m2) plus cisplatin 75 mg/m2 administered by intravenous (IV) infusion once every 3 weeks for 4 cycles without progression followed by gefitinib 250 mg administered orally, once daily, until disease progression or unacceptable toxicity."},{"id":"BG001","title":"Pemetrexed/Cisplatin","description":"Pemetrexed 500 milligrams per meters squared (mg/m2) plus cisplatin 75 mg/m2 administered by intravenous (IV) infusion once every 3 weeks for 4 cycles without progression followed by pemetrexed 500 mg/m2 administered by IV infusion (with optional cisplatin 75 mg/m2 for up to 2 additional cycles) until disease progression or unacceptable toxicity."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"39"},{"groupId":"BG001","value":"31"},{"groupId":"BG002","value":"70"}]}],"measures":[{"title":"Age Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"55.6","spread":"8.45"},{"groupId":"BG001","value":"55.7","spread":"12.43"},{"groupId":"BG002","value":"55.7","spread":"10.32"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"55"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"15"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"Participants","classes":[{"title":"East Asian","categories":[{"measurements":[{"groupId":"BG000","value":"39"},{"groupId":"BG001","value":"31"},{"groupId":"BG002","value":"70"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Taiwan","categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"21"}]}]},{"title":"China","categories":[{"measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"30"}]}]},{"title":"Korea, Republic of","categories":[{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"19"}]}]}]},{"title":"Eastern Cooperative Oncology Group (ECOG) Performance Status","description":"Classifies patients according to their functional impairment. Scores range from 0 (Fully Active) to 5 (Death). 0 - Fully Active. 1 - Ambulatory, Restricted Strenuous Activity. 2 - Ambulatory, No Work Activities. 3 - Partially Confined to Bed, Limited Self Care. 4 - Completely Disabled.","paramType":"NUMBER","unitOfMeasure":"Units on a scale","classes":[{"title":"0","categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"24"}]}]},{"title":"1","categories":[{"measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"46"}]}]}]},{"title":"History of Smoking","paramType":"NUMBER","unitOfMeasure":"Participants","classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"BG000","value":"39"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"68"}]}]}]},{"title":"Basis of Diagnosis","paramType":"NUMBER","unitOfMeasure":"Participants","classes":[{"title":"Histopathological","categories":[{"measurements":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"52"}]}]},{"title":"Cytological","categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"18"}]}]}]},{"title":"Pathological Diagnosis","paramType":"NUMBER","unitOfMeasure":"Participants","classes":[{"title":"Mixed Cell Carcinoma, Lung","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}]}]},{"title":"Adenocarcinoma","categories":[{"measurements":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"54"}]}]},{"title":"Carcinoma, Squamous Cell","categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"11"}]}]},{"title":"Non-Small Cell Lung Carcinoma","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"}]}]}]},{"title":"Disease Stage","description":"Stage means how big the tumor is and how far it has spread. Stages range from 0 (not spread) to IV (spread throughout the body). Stage 0 - the cancer has not spread beyond the inner lining of the lung. Stage I - the cancer is small and hasn't spread to the lymph nodes. Stage II - the cancer has spread to some lymph nodes near the original tumor. Stage III - the cancer has spread to nearby tissue or spread to far away lymph nodes. Stage IV - the cancer has spread to other organs of the body such as the other lung, brain, or liver.","paramType":"NUMBER","unitOfMeasure":"Participants","classes":[{"title":"Stage IIIB","categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"10"}]}]},{"title":"Stage IV","categories":[{"measurements":[{"groupId":"BG000","value":"33"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"60"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-Free Survival (PFS)","description":"Defined as the time from randomization to the first observation of disease progression, or death due to any cause.","populationDescription":"Randomized and treated (RT) population includes all randomized patients. Patients are analyzed according to the treatment they actually received (intent-to-treat \\[ITT\\] analysis). Patients were censored from this analysis (8 pemetrexed/cisplatin/gefitinib and 11 pemetrexed/cisplatin).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Baseline to first observation of disease progression or death, 12 weeks up to 31 months","groups":[{"id":"OG000","title":"Pemetrexed/Cisplatin/Gefitinib","description":"Pemetrexed 500 milligrams per meters squared (mg/m2) plus cisplatin 75 mg/m2 administered by intravenous (IV) infusion once every 3 weeks for 4 cycles without progression followed by gefitinib 250 mg administered orally, once daily, until disease progression or unacceptable toxicity."},{"id":"OG001","title":"Pemetrexed/Cisplatin","description":"Pemetrexed 500 milligrams per meters squared (mg/m2) plus cisplatin 75 mg/m2 administered by intravenous (IV) infusion once every 3 weeks for 4 cycles without progression followed by pemetrexed 500 mg/m2 administered by IV infusion (with optional cisplatin 75 mg/m2 for up to 2 additional cycles) until disease progression or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"31"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.95","lowerLimit":"5.85","upperLimit":"16.49"},{"groupId":"OG001","value":"6.83","lowerLimit":"5.78","upperLimit":"7.98"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0618","statisticalMethod":"Log Rank","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Number of Participants With Tumor Response","description":"Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes not meeting above criteria. Responder is a participant exhibiting a best overall study response of CR or PR.","populationDescription":"Qualified for Response population includes all treated patients with measurable disease prior first dose of study therapy.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Baseline to measured response or death, 12 weeks up to 31 months","groups":[{"id":"OG000","title":"Pemetrexed/Cisplatin/Gefitinib","description":"Pemetrexed 500 milligrams per meters squared (mg/m2) plus cisplatin 75 mg/m2 administered by intravenous (IV) infusion once every 3 weeks for 4 cycles without progression followed by gefitinib 250 mg administered orally, once daily, until disease progression or unacceptable toxicity."},{"id":"OG001","title":"Pemetrexed/Cisplatin","description":"Pemetrexed 500 milligrams per meters squared (mg/m2) plus cisplatin 75 mg/m2 administered by intravenous (IV) infusion once every 3 weeks for 4 cycles without progression followed by pemetrexed 500 mg/m2 administered by IV infusion (with optional cisplatin 75 mg/m2 for up to 2 additional cycles) until disease progression or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"31"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","lowerLimit":"30.1","upperLimit":"62.8"},{"groupId":"OG001","value":"11","lowerLimit":"19.2","upperLimit":"54.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.369","statisticalMethod":"Regression, Logistic","statisticalComment":"Used the Wald Chi-squared statistic from a logistic regression analysis.","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Duration of Response for Responders","description":"The duration of a complete response (CR; the disappearance of all target lesions) or partial response (PR; at least a 30% decrease in the sum of the longest diameter of target lesions) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause. A responder is a patient exhibiting a best overall study response of CR or PR.","populationDescription":"Qualified for Response population includes all treated patients with measurable disease prior first dose of study therapy. Patients were censored for this analysis (2 pemetrexed/cisplatin/gefitinib and 2 pemetrexed/cisplatin).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Time of response to progressive disease or death, 12 weeks up to 31 months","groups":[{"id":"OG000","title":"Pemetrexed/Cisplatin/Gefitinib","description":"Pemetrexed 500 milligrams per meters squared (mg/m2) plus cisplatin 75 mg/m2 administered by intravenous (IV) infusion once every 3 weeks for 4 cycles without progression followed by gefitinib 250 mg administered orally, once daily, until disease progression or unacceptable toxicity."},{"id":"OG001","title":"Pemetrexed/Cisplatin","description":"Pemetrexed 500 milligrams per meters squared (mg/m2) plus cisplatin 75 mg/m2 administered by intravenous (IV) infusion once every 3 weeks for 4 cycles without progression followed by pemetrexed 500 mg/m2 administered by IV infusion (with optional cisplatin 75 mg/m2 for up to 2 additional cycles) until disease progression or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"11"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.29","lowerLimit":"8.51","upperLimit":"15.31"},{"groupId":"OG001","value":"4.14","lowerLimit":"2.76","upperLimit":"7.62"}]}]}]},{"type":"POST_HOC","title":"Percentage of Participants Who Died During the Study","description":"This outcome measure takes the place of the outcome measure for Overall Survival, which could not be reported since the median value could not be calculated.","populationDescription":"Randomized and treated population includes all randomized patients. Patients are analyzed according to the treatment they actually received (ITT population). 25 participants from each treatment group were censored.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"Baseline up to 31 months","groups":[{"id":"OG000","title":"Pemetrexed/Cisplatin/Gefitinib","description":"Pemetrexed 500 milligrams per meters squared (mg/m2) plus cisplatin 75 mg/m2 administered by intravenous (IV) infusion once every 3 weeks for 4 cycles without progression followed by gefitinib 250 mg administered orally, once daily, until disease progression or unacceptable toxicity."},{"id":"OG001","title":"Pemetrexed/Cisplatin","description":"Pemetrexed 500 milligrams per meters squared (mg/m2) plus cisplatin 75 mg/m2 administered by intravenous (IV) infusion once every 3 weeks for 4 cycles without progression followed by pemetrexed 500 mg/m2 administered by IV infusion (with optional cisplatin 75 mg/m2 for up to 2 additional cycles) until disease progression or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"31"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.9"},{"groupId":"OG001","value":"19.4"}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact. Median overall survival could not be estimated as most participants were living at the end of the study. 25 participants from each treatment group were censored. In place of this outcome measure, the percentage of participants who died during the study are provided in the Post-Hoc Analysis Outcome Measure: Percentage of Participants Who Died During the Study.","populationDescription":"Randomized and treated population includes all randomized patients. Patients are analyzed according to the treatment they actually received (ITT population). Median overall survival could not be estimated as most participants were living at the end of the study.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Baseline to date of death from any cause, 12 weeks up to 31 months","groups":[{"id":"OG000","title":"Pemetrexed/Cisplatin/Gefitinib","description":"Pemetrexed 500 milligrams per meters squared (mg/m2) plus cisplatin 75 mg/m2 administered by intravenous (IV) infusion once every 3 weeks for 4 cycles without progression followed by gefitinib 250 mg administered orally, once daily, until disease progression or unacceptable toxicity."},{"id":"OG001","title":"Pemetrexed/Cisplatin","description":"Pemetrexed 500 milligrams per meters squared (mg/m2) plus cisplatin 75 mg/m2 administered by intravenous (IV) infusion once every 3 weeks for 4 cycles without progression followed by pemetrexed 500 mg/m2 administered by IV infusion (with optional cisplatin 75 mg/m2 for up to 2 additional cycles) until disease progression or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","eventGroups":[{"id":"EG000","title":"Pemetrexed/Cisplatin/Gefitinib","description":"Pemetrexed 500 milligrams per meters squared (mg/m2) plus cisplatin 75 mg/m2 administered by intravenous (IV) infusion once every 3 weeks for 4 cycles without progression followed by gefitinib 250 mg administered orally, once daily, until disease progression or unacceptable toxicity.","seriousNumAffected":6,"seriousNumAtRisk":39,"otherNumAffected":38,"otherNumAtRisk":39},{"id":"EG001","title":"Pemetrexed/Cisplatin","description":"Pemetrexed 500 milligrams per meters squared (mg/m2) plus cisplatin 75 mg/m2 administered by intravenous (IV) infusion once every 3 weeks for 4 cycles without progression followed by pemetrexed 500 mg/m2 administered by IV infusion (with optional cisplatin 75 mg/m2 for up to 2 additional cycles) until disease progression or unacceptable toxicity.","seriousNumAffected":3,"seriousNumAtRisk":31,"otherNumAffected":31,"otherNumAtRisk":31}],"seriousEvents":[{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":39},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":31}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":39},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":31}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":39},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":31}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":39},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":31}]},{"term":"Acute tonsillitis","organSystem":"Infections and infestations","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":39},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":31}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":31}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":39},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":31}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":39},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":31}]},{"term":"Coma","organSystem":"Nervous system disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":39},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":31}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":39},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":31}]},{"term":"Depressed mood","organSystem":"Psychiatric disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":39},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":31}]},{"term":"Apnoeic attack","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":39},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":31}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":31}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":39},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":31}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":39},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":31}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":39},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":31}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":31}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":39},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":31}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":39},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":31}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":5,"numAtRisk":39},{"groupId":"EG001","numEvents":5,"numAffected":3,"numAtRisk":31}]},{"term":"Dry eye","organSystem":"Eye disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":39},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":31}]},{"term":"Vision blurred","organSystem":"Eye disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":39},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":31}]},{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":39},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":31}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":39},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":31}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":39},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":31}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":39},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":31}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":7,"numAtRisk":39},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":31}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":10,"numAtRisk":39},{"groupId":"EG001","numEvents":5,"numAffected":3,"numAtRisk":31}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":39},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":31}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":63,"numAffected":27,"numAtRisk":39},{"groupId":"EG001","numEvents":45,"numAffected":20,"numAtRisk":31}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":8,"numAtRisk":39},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":31}]},{"term":"Toothache","organSystem":"Gastrointestinal disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":39},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":31}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":52,"numAffected":19,"numAtRisk":39},{"groupId":"EG001","numEvents":29,"numAffected":15,"numAtRisk":31}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":3,"numAtRisk":39},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":31}]},{"term":"Chest discomfort","organSystem":"General disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":39},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":31}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":39},{"groupId":"EG001","numEvents":7,"numAffected":3,"numAtRisk":31}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":10,"numAtRisk":39},{"groupId":"EG001","numEvents":9,"numAffected":5,"numAtRisk":31}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":39},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":31}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":39},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":31}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":39},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":31}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":39},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":31}]},{"term":"Cystitis","organSystem":"Infections and infestations","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":39},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":31}]},{"term":"Empyema","organSystem":"Infections and infestations","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":39},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":31}]},{"term":"Paronychia","organSystem":"Infections and infestations","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":39},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":31}]},{"term":"Rhinitis","organSystem":"Infections and infestations","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":39},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":31}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":39},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":31}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":39},{"groupId":"EG001","numEvents":11,"numAffected":6,"numAtRisk":31}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":39},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":31}]},{"term":"Creatinine renal clearance decreased","organSystem":"Investigations","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":39},{"groupId":"EG001","numEvents":8,"numAffected":4,"numAtRisk":31}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":39},{"groupId":"EG001","numEvents":12,"numAffected":11,"numAtRisk":31}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":8,"numAtRisk":39},{"groupId":"EG001","numEvents":26,"numAffected":13,"numAtRisk":31}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":39},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":31}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":6,"numAtRisk":39},{"groupId":"EG001","numEvents":14,"numAffected":8,"numAtRisk":31}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":35,"numAffected":19,"numAtRisk":39},{"groupId":"EG001","numEvents":24,"numAffected":15,"numAtRisk":31}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":31}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":39},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":31}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":31}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":39},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":31}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":39},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":31}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":39},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":31}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":39},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":31}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":39},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":31}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":39},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":31}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":6,"numAtRisk":39},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":31}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":39},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":31}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":39},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":31}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":6,"numAtRisk":39},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":31}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":39},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":31}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":39},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":31}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":9,"numAtRisk":39},{"groupId":"EG001","numEvents":7,"numAffected":4,"numAtRisk":31}]},{"term":"Pollakiuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":39},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":31}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":9,"numAtRisk":39},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":31}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":6,"numAtRisk":39},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":31}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":39},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":31}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":39},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":31}]},{"term":"Pulmonary haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":39},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":31}]},{"term":"Rhinitis allergic","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":39},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":31}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":39},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":31}]},{"term":"Dermatitis acneiform","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":39},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":31}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":39},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":31}]},{"term":"Exfoliative rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":39},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":31}]},{"term":"Nail disorder","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":39},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":31}]},{"term":"Palmar-plantar erythrodysaesthesia syndrome","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":39},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":31}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":29,"numAffected":14,"numAtRisk":39},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":31}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":13,"numAtRisk":39},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":31}]},{"term":"Skin exfoliation","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":39},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":31}]},{"term":"Skin hyperpigmentation","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":39},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":31}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"Median overall survival cannot be estimated due to the high censor rate (25 participants per treatment group were censored). Most participants were still living at the end of the study."},"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","phone":"800-545-5979"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000068437","term":"Pemetrexed"},{"id":"D002945","term":"Cisplatin"},{"id":"D000077156","term":"Gefitinib"}],"ancestors":[{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"},{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017672","term":"Nitrogen Compounds"},{"id":"D017671","term":"Platinum Compounds"},{"id":"D011799","term":"Quinazolines"}]}},"hasResults":true}